Deep Medicine Acquisition Corp. Rights
DMAQR
DMAQR was delisted on the 31st of January, 2024.
29 hedge funds and large institutions have $1.29M invested in Deep Medicine Acquisition Corp. Rights in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 3 closing their positions.
3% less capital invested
Capital invested by funds: $1.34M → $1.29M (-$43.9K)
3% less funds holding
Funds holding: 30 → 29 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$131K |
| 2 |
Walleye Capital
New York
|
+$16.4K |
| 3 |
CS
Clear Street
New York
|
+$16.3K |
| 4 |
Walleye Trading
New York
|
+$9.21K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$65 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$311K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$21.3K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$14.3K |
| 4 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$6.89K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$6.33K |
DMAQR Hedge Fund Activity: Q2 2023 in Review
29 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q2 2023, worth a combined $1.29M — down 3.3% from $1.34M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of DMAQR and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 3 added.
The largest buyer was Highbridge Capital Management, adding an estimated $131K. The largest seller was Cowen and Company, cutting an estimated $311K.
- 29 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $1.29M of Deep Medicine Acquisition Corp. Rights stock for Q2 2023, down 3.3% quarter-over-quarter.
- 2 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest Deep Medicine Acquisition Corp. Rights buyer in Q2 2023 was Highbridge Capital Management, an estimated $131K added.
- The largest Deep Medicine Acquisition Corp. Rights seller in Q2 2023 was Cowen and Company, an estimated $311K sold.
Based on aggregated 13F filings for Q2 2023.